How effective is platinib in the treatment of wild-type lung adenocarcinoma?

Platinib, as a new generation of RET inhibitors, has achieved remarkable results in the treatment of RET fusion-positive non-small cell lung cancer (NSCLC). However, what is the therapeutic effect when faced with wild-type lung adenocarcinoma?

Platinib mainly exerts its anti-tumor effect by inhibiting the activity of RET kinase. This inhibitory effect is particularly pronounced in lung cancers with RET fusions or mutations. However, there are differences in the driver gene mutations of wild-type lung adenocarcinoma and RET fusion or mutation lung cancer, so the therapeutic effect of Platinib may not be as significant as that of RET mutant lung cancer.

Current clinical trials on platinib mainly focus onRETfusion-positiveNSCLC patients. For example, the ARROW study showed that platinib achieved impressive efficacy in this group of patients, but data on patients with wild-type lung adenocarcinoma are relatively scarce. Therefore, we cannot directly apply the efficacy data of platinib in RETmutant lung cancer to wild-type lung adenocarcinoma.

Treatment strategies for wild-type lung adenocarcinoma usually include chemotherapy, radiotherapy, and immunotherapy. Although platinib is a precision treatment drug, its efficacy in wild-type lung adenocarcinoma has not been fully verified. In actual treatment, doctors need to consider the pros and cons of various treatment methods according to the patient's specific situation to formulate the best treatment plan.

To more accurately evaluate the therapeutic effect of platinib in wild-type lung adenocarcinoma, more clinical trials in this type of patients are needed in the future. At the same time, the combination of platinib and other therapeutic drugs can also be explored in order to find more effective treatment options.

The clinical therapeutic effect of platinib in wild-type lung adenocarcinoma is unclear. The current data mainly come from research on RETmutated lung cancer and cannot be directly applied to wild-type lung adenocarcinoma.